{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:05:55Z","timestamp":1790996755506,"version":"4.1.0"},"reference-count":106,"publisher":"The Korean Movement Disorder Society","issue":"2","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00209580"],"award-info":[{"award-number":["RS-2023-00209580"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["e-jmd.org"],"crossmark-restriction":true},"short-container-title":["JMD"],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:p>Parkinson\u2019s disease (PD) is the second most prevalent neurodegenerative disorder and is characterized by progressive dopaminergic and nondopaminergic neuronal loss and the presence of Lewy bodies, which are primarily composed of aggregated \u03b1-synuclein. Despite advancements in symptomatic therapies, such as dopamine replacement and deep brain stimulation, no disease-modifying therapies (DMTs) have been identified to slow or arrest neurodegeneration in patients with PD. Challenges in DMT development include disease heterogeneity, the absence of reliable biomarkers, and the multifaceted pathophysiology of PD, encompassing neuroinflammation, mitochondrial dysfunction, lysosomal impairment, and oxidative stress. Drug repositioning and repurposing strategies using existing drugs for new therapeutic applications offer promising approaches to accelerate the development of DMTs for PD. These strategies minimize time, cost, and risk by using compounds with established safety profiles. Prominent candidates include glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, ambroxol, calcium channel blockers, statins, iron-chelating agents, c-Abl inhibitors, and memantine. Although preclinical and early clinical studies have demonstrated encouraging results, numerous phase III trials have yielded unfavorable outcomes, elucidating the complexity of PD pathophysiology and the need for innovative trial designs. This review evaluates the potential of prioritized repurposed drugs for PD, focusing on their mechanisms, preclinical evidence, and clinical trial outcomes, and highlights the ongoing challenges and opportunities in this field.<\/jats:p>","DOI":"10.14802\/jmd.25008","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:55:26Z","timestamp":1738889726000},"page":"113-126","update-policy":"https:\/\/doi.org\/10.14802\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson\u2019s Disease"],"prefix":"10.14802","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4439-4390","authenticated-orcid":true,"given":"Seong Ho","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9931-8462","authenticated-orcid":true,"given":"Phil Hyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5803","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00218-x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0b013e3181a1d44c"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2019.08.002"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.03.012"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-240272"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-150685"},{"key":"ref7","first-page":"1460","volume-title":"The Parkinson\u2019s progression markers initiative (PPMI) - establishing a PD biomarker cohort","author":"Marek","year":"2018"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2016.178"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.05.001"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0b013e31824e8f0d"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12417"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000303818.38960.44"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa262"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000535"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04131-9"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.841"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-230363"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1089\/adt.2015.29011.tiodrrr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(06)69705-5"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2013.741580"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.01.013"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2016.10.001"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-5-19"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2015.06.054"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0051-5"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1172\/jci68295"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31585-4"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2312323"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00378-2"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.98.18_supplement.3068"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-47920-6_42"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.ijp_384_20"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-017-0331-6"},{"key":"ref34","first-page":"700","volume-title":"Neuroprotective effects of vildagliptin in rat rotenone Parkinson\u2019s disease model: role of RAGE-NF\u03baB and Nrf2-antioxidant signaling pathways","author":"Abdelsalam","year":"2015"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.10.007"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-014-6539-4"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2009.08.003"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12361"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26734"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49870-z"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab015"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/368703"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.2c00733"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m109.012393"},{"key":"ref45","first-page":"1651","volume-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","author":"Sidransky","year":"2009"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-140"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2013.849003"},{"key":"ref48","first-page":"e21967","volume-title":"Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate","author":"Migdalska-Richards","year":"2017"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24790"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu020"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddw129"},{"key":"ref52","first-page":"427","volume-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","author":"Mullin","year":"2020"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1252-3"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1163184"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29401"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2011.04.007"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1038\/nature05865"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21937"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25639"},{"key":"ref60","first-page":"591","volume-title":"Isradipine versus placebo in early Parkinson disease: a randomized trial","year":"2020"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29367"},{"key":"ref62","first-page":"334","volume-title":"Re-analysis of the STEADY-PD II trial-evidence for slowing the progression of Parkinson\u2019s disease","author":"Surmeier","year":"2022"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2014.10.2.140"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2008.05254.x"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2012.06.050"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.23329"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2006.12.011"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0b013e31829d873c"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000286942.14552.51"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26152"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27609"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab292"},{"key":"ref73","first-page":"1232","volume-title":"Evaluation of simvastatin as a disease-modifying treatment for patients with Parkinson disease: a randomized clinical trial","author":"Stevens","year":"2022"},{"key":"ref74","first-page":"1229","volume-title":"A double-blind, randomized, controlled trial of lovastatin in early-stage Parkinson\u2019s disease","author":"Lin","year":"2021"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27275"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2017.01.004"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2019.06.024"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2013.5593"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01402-2"},{"key":"ref80","first-page":"2045","volume-title":"Trial of deferiprone in Parkinson\u2019s disease","author":"Devos","year":"2022"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X241300295"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-171191"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1172\/jci85456"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1038\/srep04874"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-160867"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-160975"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4200"},{"key":"ref88","first-page":"312","volume-title":"Efficacy of nilotinib in patients with moderately advanced Parkinson disease: a randomized clinical trial","author":"Simuni","year":"2021"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.12.075"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2021.113810"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(10)70194-0"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12264"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.1c07591"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0310-y"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173815"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1308577"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf3934"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101670"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(07)70327-7"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1172\/jci129987"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00477-1"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.5157"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.11.022"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10121935"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.0c00722"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.110002"}],"container-title":["Journal of Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-jmd.org\/upload\/pdf\/jmd-25008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-jmd.org\/journal\/view.php?doi=10.14802\/jmd.25008","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-jmd.org\/upload\/pdf\/jmd-25008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T02:00:23Z","timestamp":1746151223000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-jmd.org\/journal\/view.php?doi=10.14802\/jmd.25008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.14802\/jmd.25008","relation":{},"ISSN":["2005-940X","2093-4939"],"issn-type":[{"value":"2005-940X","type":"print"},{"value":"2093-4939","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"2025-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-30","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}